Evidence map›Paper›PMID 32050984›Full record

ArticleOrphanet journal of rare diseases2020

Machine learning application for development of a data-driven predictive model able to investigate quality of life scores in a rare disease.

Ottavia Spiga, Vittoria Cicaloni, Cosimo Fiorini, Alfonso Trezza, Anna Visibelli, Lia Millucci, Giulia Bernardini, Andrea Bernini, Barbara Marzocchi, Daniela Braconi and 2 more

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Alkaptonuria.Nature reviews. Disease primers · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Ottavia SpigaDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy. ottavia.spiga@unisi.it.ORCID 0000-0002-0263-7107
Vittoria CicaloniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy.
Cosimo FioriniEnergy way, Modena, Italy.
Alfonso TrezzaDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy.
Anna VisibelliDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy.
Lia MillucciDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy.
Giulia BernardiniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy.
Andrea BerniniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy.
Barbara MarzocchiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy.
Daniela BraconiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy.
Filippo PrischiSchool of Life Sciences, University of Essex, Colchester, CO4 3SQ, UK.
Annalisa SantucciDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A., 53100, Siena, Italy.
University of Siena · ITUniversity of Essex · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlkaptonuria (AKU) is an ultra-rare autosomal recessive disease caused by a mutation in the homogentisate 1,2-dioxygenase (HGD) gene. One of the main obstacles in studying AKU, and other ultra-rare diseases, is the lack of a standardized methodology to assess disease severity or response to treatment. Quality of Life scores (QoL) are a reliable way to monitor patients' clinical condition and health status. QoL scores allow to monitor the evolution of diseases and assess the suitability of treatments by taking into account patients' symptoms, general health status and care satisfaction. However, more comprehensive tools to study a complex and multi-systemic disease like AKU are needed. In this study, a Machine Learning (ML) approach was implemented with the aim to perform a prediction of QoL scores based on clinical data deposited in the ApreciseKUre, an AKU- dedicated database.

methodData derived from 129 AKU patients have been firstly examined through a preliminary statistical analysis (Pearson correlation coefficient) to measure the linear correlation between 11 QoL scores. The variable importance in QoL scores prediction of 110 ApreciseKUre biomarkers has been then calculated using XGBoost, with K-nearest neighbours algorithm (k-NN) approach. Due to the limited number of data available, this model has been validated using surrogate data analysis.

resultsWe identified a direct correlation of 6 (age, Serum Amyloid A, Chitotriosidase, Advanced Oxidation Protein Products, S-thiolated proteins and Body Mass Index) out of 110 biomarkers with the QoL health status, in particular with the KOOS (Knee injury and Osteoarthritis Outcome Score) symptoms (Relative Absolute Error (RAE) 0.25). The error distribution of surrogate-model (RAE 0.38) was unequivocally higher than the true-model one (RAE of 0.25), confirming the consistency of our dataset. Our data showed that inflammation, oxidative stress, amyloidosis and lifestyle of patients correlates with the QoL scores for physical status, while no correlation between the biomarkers and patients' mental health was present (RAE 1.1).

conclusionsThis proof of principle study for rare diseases confirms the importance of database, allowing data management and analysis, which can be used to predict more effective treatments.

Indexed as

AlkaptonuriaQuality of LifeData ManagementHumansMachine LearningRare DiseasesAlkaptonuriaMachine learningPrecision medicineQoL scoresRare disease

Identifiers

PMID32050984
PMCPMC7017449
OpenAlexW3007628380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.